UnitedHealth

UnitedHealth Group closed May 12, 2026 at $384.38 — within 1% of the all-time high of $387 and up 64% from the December 2024 crash low of $234. The $349B market cap recovery is one of the most remarkable in recent S&P 500 history given what UNH endured: Brian Thompson's December 2024 assassination, the February 2024 Change Healthcare cyberattack ($3.5B total cost), and the 2024–2025 Medicare-Advantage utilization shock that compressed MLR (medical-loss ratio) from 83.5% to 88.6%.

Q1/2026 showed the operational turnaround was real, not a sentiment rally. Total revenue: $109.6B (+2.0% YoY — slow but stable). Medicare Advantage MLR: 85.2% (down from 87.8% Q1/2025), the first quarterly improvement in 6 quarters. Optum Health operating income grew +18%, OptumRx +9%, Optum Insight +15%. The combined Optum complex (which represents 50%+ of total UNH operating income) is the structural growth engine that the insurance-focused-headline-noise misses.

The Andrew Witty CEO transition (announced May 2025, completed January 2026) brought Stephen Hemsley back as Executive Chairman — Hemsley was CEO from 2006 to 2017 and oversaw UNH's 8× compounding. The market read of Hemsley returning as a positive signal: management is bringing back the team that built UnitedHealth's institutional advantages. The new CEO is Tim Noel (formerly head of Optum Health). The combined leadership change has accelerated the operational stabilization narrative.

UnitedHealth's institutional ownership rotated dramatically through the 2024–2026 crisis-and-recovery cycle. Q4/2024 sellers (Wellington, Capital Group reduced positions) at $235–$280 missed the recovery. Q1–Q2/2025 contrarian buyers — Pershing Square (Bill Ackman, initiated 2.1M shares at $280 in February 2025), Sequoia Capital Public Equity (3.4M shares at $300 in April 2025), and Baillie Gifford (added 4.8M shares at $295) — captured the bulk of the recovery.

Berkshire Hathaway briefly held a small UnitedHealth position (700,000 shares disclosed Q1/2025 13F at average ~$260), and the position was exited by Q4/2025 at $380. Berkshire bought and sold within 9 months — generating roughly $80M of profit on the trade. This is unusual for Berkshire and indicates Buffett saw a clear undervalued mispricing in early 2025 but did not see structural long-term hold rationale at the recovered level.

Insider activity (Form 4): Stephen Hemsley (Executive Chairman as of January 2026) holds 540,000 shares from his prior CEO tenure — has not sold any since returning. New CEO Tim Noel was granted 850,000 restricted-share units at the January 2026 transition, fully time-vesting over 3 years. CFO John Rex sold 22,000 shares in March 2026 at $375 (10b5-1 routine). No insider purchases since the December 2024 crisis-buying-cluster.

UnitedHealth trades at a forward P/E of 18.5, EV/EBITDA of 13.2, and free-cash-flow yield of 4.9% as of May 2026. Comparable managed-care peers — Elevance Health (forward P/E 13.4), Humana (forward P/E 10.8), Cigna (forward P/E 10.6) — show UNH at a meaningful premium. The premium reflects Optum's growth contribution (peers do not have equivalent vertical-integration). Sum-of-the-parts: Insurance (UnitedHealthcare) at $180/share (12× $14B insurance operating income), Optum Health at $80/share, OptumRx at $50/share, Optum Insight at $35/share, net cash at $40/share — total $385/share, essentially current price. Wall Street median price target $387.27 (1% upside) — analyst consensus has caught up; further upside requires continued operational beats. Dispersion: $287 (Bernstein, regulatory bear) to $444 (UBS, full-recovery bull). The 2.3% dividend with ~3% buyback yield = 5.3% baseline return.

1. July 15, 2026: Q2/2026 earnings — MA-MLR trajectory below 85% would meaningfully extend the recovery narrative
2. October 2026: CMS 2027 Medicare Advantage star ratings — direction shift versus 2025 4.3-star average drives 2027 revenue
3. 2027 (uncertain): PBM-divestiture legislation outcome — passage forces OptumRx separation; failure removes 2-year overhang

UnitedHealth at $384 is a position I would have aggressively added at $250 during the December 2024 crash; at $384 the asymmetry is mostly captured and I do not add. The Pershing Square + Sequoia entries at $280–$300 were correct contrarian calls. The Hemsley return is genuine positive — operational execution should be reliable. But the forward P/E of 18.5 is at the historical median, the 98% 52-week position leaves no error margin, and the regulatory tail-risk (PBM divestiture, star-rating cuts) is real and not fully priced. My add-trigger is below $310 (sub-15× forward) which would require a regulatory shock or broader healthcare sector weakness. For long-term holders who entered in the $234–$320 range, holding makes sense; for fresh entrants, the asymmetry that existed in 2024–2025 is no longer available. Watching from the sidelines.